Caribou, MaxCyte enter CRISPR license agreement

By The Science Advisory Board staff writers

May 7, 2020 -- Caribou Biosciences and MaxCyte have announced a clinical and commercial license agreement for the development of Carbiou's CAR-T cell therapy program.

Under the agreement, Caribou gains rights to the use of MaxCyte's Flow Electroporation technology and ExPert platform for advancement of its CRISPR gene-edited allogenic T-cell therapy. Caribou will obtain nonexclusive clinical and commercial rights to the platform and in return MaxCyte will receive undisclosed development and approval milestones and sales-based payments in addition to licensing fees.
Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
ESMO Virtual Congress 2020
September 14-29
Online
BioProcess International West
September 21-25
Online
BioProcess International
September 21-25
Online
ASGCT 2020 Policy Summit
September 23-25
Online
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter